Press release - 15/01/2008 ALVESCO® gains FDA approval for the U.S. market The Food and Drug Administration approved Nycomeds ALVESCO ciclesonide Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.https://www.gesundheitsindustrie-bw.de/en/article/press-release/alvesco-gains-fda-approval-for-the-u-s-market